Aims: This review provides evidence of which interventions need to be part of effective outpatient integrated treatment for patients with comorbid schizophrenia and substance use disorders. Methods: A total of 14 randomized controlled trials were included. Effect sizes are provided to assess the magnitude of the treatments' efficacy. Results: Despite the studies' heterogeneity, we can conclude that certain programs (e.g. Behavioral Treatment for Substance Abuse in Severe and Persistent Mental Illness ) and specific interventions (e.g. motivational interviewing, family interventions) seem to be effective. Moreover, programs integrating multiple interventions are more likely to be positively related to better outcomes than single interventions. Finally, the lack of difference between effect sizes of assertive community treatment compared to case management suggests that a lower caseload is not necessary for positive treatment outcomes. Conclusion: Integrated treatment seems advantageous, although effect sizes are mostly modest. More homogeneous and qualitative sound studies are needed.

Keywords:
Dual disorder, Schizophrenia, Substance use disorder, Randomized controlled trial, Efficacy
1.
Juola P, Miettunen J, Veijola J, Isohanni M, Jaaskelainen E: Predictors of short- and long-term clinical outcome in schizophrenic psychosis - the Northern Finland 1966 Birth Cohort study. Eur Psychiatry 2013;28:263-268.
2.
Buhler B, Hambrecht M, Loffler W, an der Heiden W, Hafner H: Precipitation and determination of the onset and course of schizophrenia by substance abuse - a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res 2002;54:243-251.
3.
Horsfall J, Cleary M, Hunt GE, Walter G: Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence. Harv Rev Psychiatry 2009;17:24-34.
4.
Linszen DH, Dingemans PM, Lenior ME: Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994;51:273-279.
5.
Mueser KT, Noordsy DL, Drake RE, Fox L: Integrated Treatment for Dual Disorders. A Guide to Effective Practice. New York, Guilford Press, 2003.
6.
Petersen L, Jeppesen P, Thorup A, Ohlenschlaeger J, Krarup G, Ostergard T, Jorgensen P, Nordentoft M: Substance abuse and first-episode schizophrenia-spectrum disorders. The Danish OPUS trial. Early Interv Psychiatry 2007;1:88-96.
7.
Van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H: Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002;156:319-327.
8.
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-2518.
9.
Swendsen J, Ben-Zeev D, Granholm E: Real-time electronic ambulatory monitoring of substance use and symptom expression in schizophrenia. Am J Psychiatry 2011;168:202-209.
10.
Drake RE, McHugo GJ, Clark RE, Teague GB, Xie H, Miles K, Ackerson TH: Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial. Am J Orthopsychiatry 1998;68:201-215.
11.
McHugo GJ, Drake RE, Teague GB, Xie H: Fidelity to assertive community treatment and client outcomes in the New Hampshire dual disorders study. Psychiatr Serv 1999;50:818-824.
12.
Brunette MF, Mueser KT, Drake RE: A review of research on residential programs for people with severe mental illness and co-occurring substance use disorders. Drug Alcohol Rev 2004;23:471-481.
13.
Drake RE, O'Neal EL, Wallach MA: A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat 2008;34:123-138.
14.
Morrens M, Dewilde B, Sabbe B, Dom G, De Cuyper R, Moggi F: Treatment outcomes of an integrated residential programme for patients with schizophrenia and substance use disorder. Eur Addict Res 2011;17:154-163.
15.
Drake RE, Latimer E: Lessons learned in developing community mental health care in North America. World Psychiatry 2012;11:47-51.
16.
Thornicroft G, Tansella M: The balanced care model for global mental health. Psychol Med 2013;43:849-863.
17.
Schulte SJ, Meier PS, Stirling J: Dual diagnosis clients' treatment satisfaction - a systematic review. BMC Psychiatry 2011;11:64.
18.
Thalheimer W, Cook S: How to calculate effect sizes from published research: a simplified methodology. 2002. Retrieved from http://www.bwgriffin.com/gsu/courses/edur9131/content/Effect_Sizes_pdf5.pdf.
19.
Graeber DA, Moyers TB, Griffith G, Guajardo E, Tonigan S: A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. Community Ment Health J 2003;39:189-202.
20.
Bien TH, Miller WR, Tonigan JS: Brief interventions for alcohol problems: a review. Addiction 1993;88:315-335.
21.
Ries RK, Dyck DG, Short R, Srebnik D, Fisher A, Comtois KA: Outcomes of managing disability benefits among patients with substance dependence and severe mental illness. Psychiatr Serv 2004;55:445-447.
22.
Martino S, Carroll KM, Nich C, Rounsaville BJ: A randomized controlled pilot study of motivational interviewing for patients with psychotic and drug use disorders. Addiction 2006;101:1479-1492.
23.
Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O'Brien R, Schofield N, McGovern J: Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 2001;158:1706-1713.
24.
Haddock G, Barrowclough C, Tarrier N, Moring J, O'Brien R, Schofield N, Quinn J, Palmer S, Davies L, Lowens I, McGovern J, Lewis S: Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial. Br J Psychiatry 2003;183:418-426.
25.
Barrowclough C, Haddock G, Wykes T, Beardmore R, Conrod P, Craig T, Davies L, Dunn G, Eisner E, Lewis S, Moring J, Steel C, Tarrier N: Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. BMJ 2010;341:c6325. DOI: 10.1136/bmj.c6325.
26.
Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y: A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry 2006;63:426-432.
27.
James W, Preston NJ, Koh G, Spencer C, Kisely SR, Castle DJ: A group intervention which assists patients with dual diagnosis reduce their drug use: a randomized controlled trial. Psychol Med 2004;34:983-990.
28.
Essock SM, Mueser KT, Drake RE, Covell NH, McHugo GJ, Frisman LK, Kontos NJ, Jackson CT, Townsend F, Swain K: Comparison of ACT and standard case management for delivering integrated treatment for co-occurring disorders. Psychiatr Serv 2006;57:185-196.
29.
Morse GA, Calsyn RJ, Dean Klinkenberg W, Helminiak TW, Wolff N, Drake RE, Yonker RD, Lama G, Lemming MR, McCudden S: Treating homeless clients with severe mental illness and substance use disorders: costs and outcomes. Community Ment Health J 2006;42:377-404.
30.
Burnam MA, Morton SC, McGlynn EA, Petersen LP, Stecher BM, Hayes C, Vaccaro JV: An experimental evaluation of residential and nonresidential treatment for dually diagnosed homeless adults. J Addict Dis 1995;14:111-134.
31.
Mueser KT, Glynn SM, Cather C, Xie H, Zarate R, Smith LF, Clark RE, Gottlieb JD, Wolfe R, Feldman J: A randomized controlled trial of family intervention for co-occurring substance use and severe psychiatric disorders. Schizophr Bull 2013;39:658-672.
32.
Mueser KT, Glynn SM, Cather C, Zarate R, Fox L, Feldman J, Wolfe R, Clark RE: Family intervention for co-occurring substance use and severe psychiatric disorders: participant characteristics and correlates of initial engagement and more extended exposure in a randomized controlled trial. Addict Behav 2009;34:867-877.
33.
Drebing CE, Van Ormer EA, Krebs C, Rosenheck R, Rounsaville B, Herz L, Penk W: The impact of enhanced incentives on vocational rehabilitation outcomes for dually diagnosed veterans. J Appl Behav Anal 2005;38:359-372.
34.
Tracy K, Babuscio T, Nich C, Kiluk B, Carroll KM, Petry NM, Rounsaville BJ: Contingency management to reduce substance use in individuals who are homeless with co-occurring psychiatric disorders. Am J Drug Alcohol Abuse 2007;33:253-258.
35.
Bond GR, McDonel EC, Miller LD, Pensec M: Assertive community treatment and reference groups: an evaluation of their effectiveness for young adults with serious mental illness and substance abuse problems. Psychosoc Rehabil J 1991;15:31-43.
36.
Jerrell JM, Ridgely MS: Comparative effectiveness of three approaches to serving people with severe mental illness and substance abuse disorders. J Nerv Ment Dis 1995;183:566-576.
37.
Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, Sly K, Devir H, Terry M: Evaluation of a motivational interview for substance use within psychiatric in-patient services. Addiction 2002;97:1329-1337.
38.
Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, Sly K, Devir H, Terry M: Motivational interviewing among psychiatric in-patients with substance use disorders. Acta Psychiatr Scand 2002;106:233-240.
39.
Herman SE, BootsMiller B, Jordan L, Mowbray CT, Brown WG, Deiz N, Bandla H, Solomon M, Green P: Immediate outcomes of substance use treatment within a state psychiatric hospital. J Ment Health Adm 1997;24:126-138.
40.
Kavanagh DJ, Young R, White A, Saunders JB, Wallis J, Shockley N, Jenner L, Clair A: A brief motivational intervention for substance misuse in recent-onset psychosis. Drug Alcohol Rev 2004;23:151-155.
41.
Martino S, Carroll KM, O'Malley SS, Rounsaville BJ: Motivational interviewing with psychiatrically ill substance abusing patients. Am J Addict 2000;9:88-91.
42.
Swanson AJ, Pantalon MV, Cohen KR: Motivational interviewing and treatment adherence among psychiatric and dually diagnosed patients. J Nerv Ment Dis 1999;187:630-635.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.